Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

142 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-22

Study Completion Date

2015-04-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose of the study:

* To assess efficacy of Anaferon for children liquid dosage form in the treatment of acute upper respiratory tract infections.
* To assess safety of Anaferon for children liquid dosage form in the treatment of acute upper respiratory tract infections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children

NCT02072174

Influenza and Acute Respiratory Viral Infections

COMPLETED PHASE4

Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI

NCT03301155

Preventive Medicine

COMPLETED PHASE4

Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections

NCT03707912

Acute Respiratory Viral Infections

COMPLETED PHASE4

Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children

NCT01843842

Acute Upper Respiratory Tract Infections

COMPLETED PHASE3

Clinical Trial of Safety and Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adults

NCT01765920

Acute Upper Respiratory Tract Infections

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Upper Respiratory Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anaferon for children

Group Type EXPERIMENTAL

Anaferon for children (liquid dosage form)

Intervention Type DRUG

10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo (liquid dosage form)

Intervention Type DRUG

10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anaferon for children (liquid dosage form)

10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.

Intervention Type DRUG

Placebo (liquid dosage form)

10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients of both sexes aged 1 month to 3 years.
2. Diagnosis of acute upper respiratory infection based on a doctor's examination of the patient: body temperature at least 37.8°C when visiting a doctor + symptom scores ≥3 (presence of at least 1 general symptom and 1 nasal/ throat/chest symptom).
3. The first 24 hours from the beginning of manifestations of acute upper respiratory infection.
4. Acute respiratory viral infections season.
5. The possibility to start treatment within 24 hours of the onset of acute upper respiratory infection symptoms.
6. Availability of a patient information sheet (Informed Consent form) signed by the patient's parents/adopters to confirm the child's participation in the clinical trial signed by one parent/adopter of patient.

Exclusion Criteria

1. Suspected pneumonia or bacterial infection or the presence of a disease requiring usage of antibacterial drugs starting from day 1 of the illness onset.
2. Clinical symptoms of severe influenza/ARI (acute respiratory infection) requiring hospitalization.
3. Suspected early manifestations of diseases that have symptoms similar to ARI symptoms (other infectious diseases, influenza-like syndrome at the onset of systemic connective tissue disorders, hematologic neoplasms and other pathology).
4. Documented (prior diagnosis) or suspected disease such as

* primary or secondary immunodeficiency: а) lymphoid immunodeficiency (T-cell and/or B-cell immunity, immunodeficiencies with predominant antibody deficit, b) phagocyte deficits; c) complement factor deficit; d) combined immunodeficiency including AIDS secondary to HIV infection; toxic, autoimmune, infectious, or radial panleukopenia syndrome; general lymphocytopenia syndrome; syndrome of lymphocyte polyclonal activation; postsplenectomia syndrome; congenital asplenia; syndrome of immune complexes pathology associated with infectious, autoimmune and allergic diseases;
* cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, congenital malformations of the respiratory system, including malformations of upper respiratory tract, and other chronic lung disease;
* malignant neoplasm.
5. Exacerbation or decompensation of chronic diseases affecting ability to participate in the clinical study.
6. Medical history of polyvalent allergy.
7. Allergy/ intolerance to any of the components of medications used in the treatment.
8. Use of medications listed in 'Prohibited concomitant treatments/medications' within 2 weeks before study entry.
9. Drug use or alcohol use (more than 2 alc. units daily) by the patient's parent(s)/adopter(s).
10. Mental disorders of patient's parent(s)/adopter(s).
11. Patients whose parents/adopters, from the investigator's point of view, will fail to comply with the observation requirements of the trial or with the intake regimen of the investigated medicines.
12. Participation in other clinical studies in the course of 3 months (or 1-2 months for infants under two months of age) prior to the inclusion in the trial.
13. Patient's parents/adopters are related to the clinical trial site's research staff directly involved in the trial or are the immediate family member of the researcher. The immediate family members include husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.
14. The patient's parent/adopter works for OOO "NPF "MATERIA MEDICA HOLDING" (i.e., the company's employee, part-time employee under contract or appointed official in charge of the trial, or their immediate family).

Minimum Eligible Age

1 Month

Maximum Eligible Age

3 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No